<DOC>
	<DOCNO>NCT00792636</DOCNO>
	<brief_summary>The purpose study test effect blood pressure sumatriptan naproxen sodium combination tablet , tablet contain sumatriptan , tablet contain naproxen sodium drug take treat migraine headache occur 6-month period .</brief_summary>
	<brief_title>A Study Determine Effect Sumatriptan Naproxen Sodium Combination Tablet , Sumatriptan Tablet , Naproxen Sodium Tablet Blood Pressure When Treating Migraine Headaches That Occur During 6-month Period</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Subjects eligible enrollment study must meet following criterion : Male female outpatient 18 65 year age . Female subject eligible participation study : Females nonchildbearing potential Females childbearing potential negative urine pregnancy test Screening agree use one GlaxoSmithKline specify highly effective method avoid pregnancy . Subjects take oral contraceptive must stable regimen least two month prior Screening . Subject migraine , without aura ( ICHDII criterion , 1.2.1 1.1 ) [ International Headache Society , 2004 ] . Subject must history two eight attack per month , average , six month prior Screening Visit . Additionally subject experience least two , eight , migraine attack per month three month prior Screening Visit . Subject able distinguish migraine attack headache ( i.e . tensiontype headache ) . Subject willing able provide write informed consent , comprehend perform requirement protocol . Exclusion criterion : Subjects meet follow criterion must enrol study : Subject ≥10 migraine attack ≥15 headache day per month total ( include migraine , probable migraine tensiontype headache ) . Subject retinal ( ICHDII 1.4 ) , basilar ( ICHDII 1.2.6 ) , hemiplegic migraine ( ICHDII 1.2.4 ) , secondary headache [ International Headache Society , 2004 ] . Subject history control uncontrolled hypertension currently take angiotensionconverting enzyme ( ACE ) inhibitor angiotension receptor blocker . Subject inclinic screening blood pressure ≥ 130/85 mmHg two three blood pressure measurement . Subject take antihypertensive medication reason include migraine prophylaxis . Subject glycosylated hemoglobin ≥ 8.0 Subject chronic condition ( i.e . osteoarthritis , rheumatoid arthritis , fibromyalgia ) require chronic daily administration nonsteroidal antiinflammatory drug ( NSAIDS ) ( include acetaminophen ) opioids opioid combination product . Subject , investigator 's opinion , likely unrecognized cardiovascular cerebrovascular disease . Subject history congenital heart disease , cardiac arrhythmia require medication , history clinically significant electrocardiogram abnormality , investigator 's opinion , contraindicate participation study . Subject evidence history ischemic vascular disease include : ischemic heart disease , ischemic abdominal syndrome , peripheral vascular disease Raynaud 's Syndrome , sign symptoms consistent . Subject evidence history central nervous system pathology include stroke and/or transient ischemic attack ( TIAs ) , epilepsy structural brain lesion lower convulsive threshold , treat antiepileptic drug seizure control within five year prior Screening . Subject history impair hepatic renal function , investigator 's opinion , contraindicate participation study . Subject hypersensitivity , allergy , intolerance contraindication use triptan , NSAID , aspirin ( include sumatriptan naproxen preparation ) nasal polyps asthma . Subject currently take , use , ergot ergotderived medication previous three month migraine prophylaxis take medication stabilize ( i.e . change dose within past two month ) chronic intermittent migraine prophylaxis comorbid condition stabilize . Subject recent history regular use opioids barbiturates treatment migraine headache and/or nonmigraine pain . Regular use define average four day per month last six month . Subject take plan take monoamine oxidase inhibitor ( MAOI ) , include herbal preparation contain St. John 's Wort ( Hypericum perforatum ) CNS stimulant medication ( atomoxetine , dextroamphetamine amephetamine product , dexmethlyphenidate , lisdexamdetamine dimesylate methylphenidate ) anytime within two week prior Screening twoweeks posttreatment . Subject history bleed disorder currently take anticoagulant antiplatelet agent . ( except lowdose aspirin &lt; =325mg/day cardioprotective reason ) . Subject evidence history gastrointestinal surgery , gastrointestinal ulceration perforation past six month , gastrointestinal bleeding past year , evidence history inflammatory bowel disease . Subject pregnant , actively try become pregnant , breast feeding subject willing pregnancy test perform require . Subject test positive illicit substance toxicology screen evidence alcohol substance abuse within last year , concurrent medical psychiatric condition , investigator 's judgment , likely interfere study conduct , subject cooperation , evaluation interpretation study result , otherwise contraindicate participation clinical trial . Subject participate investigational drug trial within previous four week plan participate another study time study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>sumatriptan naproxen sodium</keyword>
	<keyword>migraine without aura</keyword>
	<keyword>naproxen sodium</keyword>
	<keyword>sumatriptan</keyword>
	<keyword>blood pressure</keyword>
	<keyword>migraine headache</keyword>
</DOC>